Advanced Heart Failure: A Call to Action by Russell, Stuart D. et al.
R E V I E W P A P E R
Advanced Heart Failure: A Call to Action
H eart failure (HF) affects morethan 5 million patients in the
United States and is associated with
high morbidity and mortality rates.1
Despite improvements in medical
therapy with the use of angiotensin-
converting enzyme (ACE) inhibitors,
aldosterone antagonists, b-blockers, and
cardiac defibrillators, more than 250,000
people die of HF each year.1–4 Although
some of these patients die suddenly with
few symptoms of HF, it is estimated that
between 300,000 and 800,000 patients
have ‘‘advanced HF.’’ This is defined as
patients with left ventricular systolic
dysfunction who experience symptoms
that limit daily activity with poor exer-
cise capacity despite maximal therapy.5
Recommended therapies for these
patients, in addition to optimal medical
management, include biventricular pac-
ing, cardiac transplant, and mechanical
circulatory support.2–4 When patients
do not respond to these therapies, or
cannot tolerate them, hospice and palli-
ative care become the only option.
While there is significant clinical evi-
dence demonstrating that advanced HF
patients benefit from the recommended
therapies, it is often quite difficult to
determine when a patient with stable
New York Heart Association (NYHA)
functional class III will progress to
advanced-stage HF. As shown in
Figure 1, there is a continuum across
which patients with HF progress.
Recently, the American College of
Cardiology (ACC) and the American
Heart Association (AHA) developed a
stage classification system for describing
HF.6 Many patients, despite having left
ventricular dysfunction, are completely
asymptomatic and are classified as hav-
ing stage BHF. Some of these patients,
regardless of their evolution of disease
will not seek or receive medical care.
Others will be treated with optimal
medical management and will remain
stable for a period of time. Eventually,
most patients progress to developing
symptoms of HF and are classified as
having stage CHF. Presentation will
vary among patients. With time, as the
left ventricle dilates further, patients will
progress to advanced HF with symptoms
at rest or with mild exertion, known as
stage D. Patients may have periods of
decompensation that require hospitaliza-
tion but will then temporarily improve
and become less symptomatic, fluctuat-
ing between NYHA functional class III
and IV and ACC ⁄AHA stages C and
DHF. The ideal time for referral for
advanced HF therapies is when the
patient progresses from having stable HF
to having advanced HF. Often, this
referral doesn’t happen until the patient
is moribund or doesn’t happen at all.
This may occur for many reasons. Physi-
cians may not be convinced that the
advanced HF therapies available provide
superior outcomes to those they can pro-
vide without making a referral to a ter-
tiary care center. The referring physician
may not have an established referral
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Figure 1. Progression of heart failure by
American College of Cardiology (ACC)
stages. Within stage D, heart failure can
change between advanced and decompen-
sated as well as progress to refractory and
terminal.
doi: 10.1111/j.1751-7133.2008.00022.x
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pathway that allows the partnership
required to provide care for these com-
plex patients. Most common, progres-
sion of HF is often quite difficult to
predict and, when the progression
occurs, it may happen so quickly that
the patient is soon not a viable candi-
date for any of the advanced-stage
therapies.
In this article, we have 3 goals:
d Define the current field in terms of
available therapies.
d Provide guidance to referring physi-
cians who wish to identify patient
progression.
d Propose further study to validate our
model ⁄ theory.
We will begin with a review of the
current therapies and the correspond-
ing outcomes available for advanced-
stage HF patients. Also, based on pub-
lished predictors of mortality, we offer
a simple prognostic model to assist
referring physicians in determining
when their patients have progressed to
the point at which referral for
advanced-stage therapies are necessary.
Finally, we propose a study to validate
this model.
Therapies for Advanced HF
The ACC ⁄AHA 2005 update for the
diagnosis and management of HF
approaches the treatment of HF by
dividing therapies based on the patient’s
clinical stage of HF.4 Therapies vary
depending on the severity of the
patient’s disease, as outlined in Table I.
For the stage D refractory patient, opti-
mal medical and device management
includes salt and fluid restriction; use of
ACE inhibitors or angiotensin receptor
blockers, b-blockers, diuretics, and
implantable cardioverter-defibrillators
(ICDs); and, in select patients, use of
aldosterone antagonists, digitalis, hydral-
azine ⁄nitrates, and biventricular pacers.
In addition, other therapies that
should be considered include heart
transplant, chronic inotropes, perma-
nent mechanical support, and experi-
mental surgery or medications,
depending on the patient presentation
and appropriateness of these options for
the particular patient.
Heart Transplant. Cardiac transplant
is considered a preferred therapy for
appropriately selected patients with
advanced-stage HF. Transplant provides
strong outcomes, with a 50% survival
rate at 9.9 years for all patients and a
50% survival rate of 13 years for patients
who survive the initial posttransplant
year.7 Patients return to a near-normal
quality of life and functional capacity.
Due to limitations in the supply of
donor organs, however, only 2000
patients a year receive transplants in the
United States, and it is clearly not an
option for the vast majority of patients
with advanced-stage HF. In addition,
due to long waiting times for donor
organs, more than 10% of the waiting-
list patients die each year. Better thera-
peutic options must be sought to
improve outcomes and avoid mortality
for these patients.
Chronic Inotropes. Inotropes are
known for their ability to increase
contractility and improve symptoms in
the short term but are frequently associ-
ated with a mixture of negative side
effects. All inotropes can induce arrhyth-
mias and tachycardia and activate the
renin-angiotensin-aldosterone system.
Despite the routine and accepted use of
inotropes in patients with refractory HF,
inotropes have not been extensively
evaluated in this patient population.
The Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations
of Chronic Heart Failure (OPTIME-
CHF) study8 evaluated the use of milri-
none in addition to routine medical
therapy in patients admitted with HF.
Patients with predominantly NYHA III
and IV symptoms were randomized to
either a 48-hour infusion of milrinone or
placebo. There were no differences in
the number of days hospitalized within
60 days of randomization, in hospital or
60-day mortality, or the incidence of
death or readmission. However, 35% of
the patients were readmitted or had died
within the next 60 days. This study
revealed that despite an improvement in
clinical status, inpatient therapy with
milrinone for routine exacerbations of
HF is not clinically useful. In addition,
the study demonstrated that HF hospi-
talization is a marker of disease progres-
sion, with 8.9% of the placebo patients
and 10.3% of the milrinone patients
dying within the next 60 days.
This study was followed by the
Continuous Outpatient Support With
Inotropes (COSI) study.9 Thirty-six
inotrope-dependent patients (defined as
worsening of clinical status with
attempted withdrawal) were discharged
to home on long-term inotrope therapy.
These patients had truly advanced-stage
HF, with an ejection fraction of 19.9%,
systolic blood pressure of 97 mm Hg,
serum creatinine of 1.6 mg ⁄dL, and
serum sodium of 132 mEq ⁄L. The
median survival rate postdischarge was
3.4 months, and 12-month survival was
6%. Truly inotrope-dependent patients
do not do well with inotropic therapy.
Similar results were found from a retro-
spective analysis of the outcomes of
patients taking inotropes in the Ran-
domized Evaluation of Mechanical
Table I. ACC ⁄ AHA–Recommended Therapy for Heart Failure Patients by Stage6
Stage A ACE inhibitor or ARB in appropriate patients
Stage B ACE inhibitor or ARB in appropriate patients.
b-Blockers in appropriate patients
Stage C Routine Select patients
Diuretics if fluid retention Digitalis







Experimental surgery or drugs
Abbreviations: ACC, American College of Cardiology; ACE, angiotensin-converting
enzyme; AHA, American Heart Association; ARB, angiotensin receptor blocker.
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Assistance for the Treatment of Conges-
tive Heart Failure (REMATCH) trial.10
In this trial that evaluated the use of
ventricular assist devices as permanent
therapy for patients with advanced-stage
HF, 91 of 129 patients were taking ino-
tropic therapy at the time of randomiza-
tion. The survival rates in the group
that received medical therapy was 24%
at 1 year and 11% at 2 years.
Bridging patients to transplant on
inotropes is also a commonly accepted,
although minimally documented, prac-
tice. In fact, there is a mounting body of
evidence that suggests that other
advanced HF therapies, such as ventric-
ular assist devices (VADs), offer better
outcomes and decreased mortality.
Aaronson and colleagues11 reported that
in a cohort of 102 patients awaiting
heart transplant, overall survival of the
VAD patients was superior to the ino-
trope group. Bhat12 found that in 16 of
39 patients treated with an inotrope, a
VAD was still needed to successfully
bridge the patients to transplant.
Clearly, inotropes alone should not be
considered the only option for bridge to
transplant and, in fact, may negatively
impact outcomes if used inappropriately.
Ventricular Assist Devices. Left VADs
(LVADs) have been used for nearly
30 years to support patients awaiting
cardiac transplant until a suitable donor
becomes available. Until recently, how-
ever, they were limited to this small
group of patients. The REMATCH
trial13 was designed to evaluate the use
of an LVAD as a long-term permanent
therapy for patients not eligible for a
transplant. In the trial, 129 patients not
eligible for cardiac transplant were ran-
domized to either continued medical
therapy or surgery with placement of an
LVAD. The survival rate at 1 year was
52% in the LVAD group and only 25%
in the medical therapy group. Similar
improvements in survival were present
at year 2. Although quality-of-life
measurements all showed improvements
in the LVAD arm, LVAD therapy was
associated with a longer total and initial
hospital stay, more infections, and more
neurologic events. However, a follow-up
study demonstrated that many of these
outcomes improve with improved surgi-
cal experience. Long and colleagues14
reported results in 42 patients that had
an LVAD placed after the REMATCH
trial, and survival at 1 year had
improved to 61%. Despite this improve-
ment, ‘‘destination’’ therapy has still not
been widely accepted by the medical
community, except in relatively isolated
circumstances. In addition, a recently
presented study has shown that refined
patient selection is required to improve
outcomes, noting that some patients
receive VAD therapy at a point when
they are too ill to experience an optimal
outcome.15 Based on a multivariate
analysis of clinical predictors of poor
outcomes after placement of an LVAD,
a group of very high-risk patients were
identified with a greater than 90%
chance of in-hospital mortality. This
study demonstrates that there is a group
of patients that are simply too ill for a
positive outcome, thus negatively
impacting the perception of destination
therapy. Although there is not a limit to
the number of VADs that can be
implanted, as there is with transplant,
there is still a need for appropriate and
timely application of the technology.
This validates the need for development
of a simple clinical risk model to identify
patients for referral to an advanced HF
center when these advanced, proven
therapies still have the potential for
clinical benefit.
Risk Factors for Mortality
in Patients Evaluated for
Cardiac Transplant
There are a large number of bioche-
mical-, structural-, physiologic-, and
medical-based risk factors that have
been associated with mortality in
patients with HF.
The landmark Studies of Left Ven-
tricular Dysfunction (SOLVD) trial16
was the first major study in HF to evalu-
ate clinical predictors of mortality. From
this trial, retrospective analyses have
shown that elevated plasma norepineph-
rine levels, atrial fibrillation, renal insuf-
ficiency, reduced ejection fractions,
enlarged diastolic dimensions, and
diuretic use have all been shown to be
associated with an increased risk of
mortality.17–21
Similarly, others have developed risk
models for predicting mortality in
patients evaluated for cardiac transplant.
Mancini and colleagues22 first evaluated
the use of the metabolic exercise test to
determine whether the use of peak oxy-
gen consumption can help to predict
mortality. They found a direct relation-
ship between lower peak oxygen
consumption values and mortality.
In addition, they found that patients
with peak oxygen consumption
14 mL ⁄kg ⁄min had a survival advan-
tage with cardiac transplant compared
with continued medical therapy. Since
that landmark paper in 1992, peak oxy-
gen consumption has been used to
determine whether patients should be
listed for transplant. This work was later
advanced by the Heart Failure Survival
Score (HFSS).23 Aaronson and col-
leagues23 developed a risk model for HF
patients and identified low-, medium-,
and high-risk groups. Risk factors for
mortality included an ischemic etiology,
higher heart rates, lower ejection frac-
tion and mean blood pressure, presence
of an intraventricular conduction delay,
peak oxygen consumption, hyponatre-
mia, and elevated pulmonary capillary
wedge pressures. While simple, variables
such as oxygen consumption and pulmo-
nary capillary wedge pressures are rarely
obtained unless a patient is being evalu-
ated for cardiac transplant and therefore
rarely assist in determining when some-
one is ready for referral. There is still a
need for help in determining when
patients should be referred for advanced
therapies.
Risk Factors for Mortality
in Patients With HF
Table II outlines a number of studies
that have been performed in both the
inpatient and outpatient settings to
assist in determining prognosis in
patients with HF.24–39 Although the
modeling methods that were performed,
the exact variables evaluated, and
length of follow-up varies from study to
study, a consistent pattern of results are
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reported. Evidence of poor perfusion to
end organs manifested by decreased
renal function, neurohormonal upregu-
lation manifested by hyponatremia, poor
exercise tolerance manifested by both
NYHA functional class and 6-minute
walk distance, hypotension, high diure-
tic doses, inability to tolerate either an
ACE inhibitor or a b-blocker, and
recent hospitalizations are repeatedly
demonstrated to be markers of poor
patient outcomes. Many of these studies
have developed sophisticated models
using risk scores or dividing patients into
risk groups based on scores that are quite
beneficial academically but, similar to
the HFSS, are not used practically.
Furthermore, a proven, reliable, simple
clinical risk score classification that can
be calculated from memory to predict
mortality during the next year has never
been developed, especially in the
outpatient setting, despite multiple
studies that have examined various risk
factors for mortality.
As shown in Table III, we propose a
simple group of clinical markers that,
when present in patients, should predict
poor outcomes during the next year, and
their presence should trigger consider-
ation for a referral to an advanced HF
center for advanced medical and surgical
therapies not available in the commu-
nity. All of these indicators are noted dur-
ing a routine clinical visit and laboratory
evaluation and would not require addi-
tional testing. Although no prognostic
studies have been performed to evaluate
the predictive value of these variables,
based on the studies in Table II, it is quite
clear that all of these variables have been
shown to predict survival in large patient
populations. Furthermore, a prospective
trial evaluating a number of similar risk
factors should be performed. Despite mul-
tiple retrospective studies of predictors, a
prospective study specifically designed to
evaluate risk factors for mortality in
patients with HF has never been
performed. The following factors should
be included in such a study.
Exercise Tolerance. Bouvy,28 Felker,31
Mahon,35 Greenberg,37 Levy,38 and
colleagues all included either 6-minute
walk distance or NYHA functional class
in their prognostic models. We believe
that the clinically relevant ‘‘how far can
you walk before becoming short of
breath’’ question reflects this evaluation
in a practical manner. In addition, Stew-
art and colleagues40 presented a study at
the 2006 AHA Annual Meeting in
which they asked patients at what point






Chin et al24 In 257 BP <100 mm Hg, DM, nonsinus rhythm N ⁄ A
Alla et al25 In 301 HR >100 beats per minute, Na <134 mEq ⁄ L,
Creat >2.0 mg ⁄ dL, age >70 y, prior hosp
57.6
Cowie et al26 In 220 Age, crackles on examination, low BP, high Creat 62
Jong et al27 In 38,702 Male; age; malignancy; dementia; renal, cerebrovascular,
rheumatologic, peripheral vascular, or pulmonary disease;
ischemic etiology, DM
66.9
Bouvy et al28 In 152 DM, high Creat, NYHA III ⁄ IV, low BMI, low BP, edema N ⁄ A
Lee et al29 In 4031 Age, low BP, high RR, high BUN, low Na 69.5
Kittleson et al30 In 259 No ACE, low BP, low Na, high Creat N ⁄ A
Felker et al31 In 949 Age, low BP, NYHA IV, high BUN, low Na N ⁄ A
Fonarow et al32 In 37,772 BUN >43 mg ⁄ dL, systolic BP <115 mm Hg,
Creat >2.75 mg ⁄ dL
N ⁄ A
Rector et al33 In 769 Age, low BP, low Hgb, low Na, high BUN 50% (high risk)
Rohde et al34 In 779 Cancer, systolic BP <124 mm Hg, Creat >1.4 mg ⁄ dL,
BUN >37 mg ⁄ dL, Na <136 mEq ⁄ L, age >70 y
N ⁄ A
Mahon et al35 Out 585 Low Creat cl, 6 MW <262 m, low EF, recent hosp, diuretic
Eshaghian et al36 Out 1354 Low EF, low Na, low Hgb, high BUN, high Creat,
diuretic dose
Greenberg et al37 Out 4280 NYHA III ⁄ IV, HF hosp, angina
Levy et al38 Out 1125 Diuretic dose, low BP, % lymph, Hgb <16 g ⁄ dL, ischemic
etiology, EF, low cholesterol, high uric acid ⁄ allopurinol use,
Na <138 mEq ⁄ L, NYHA, age, male sex
Teuteberg et al39 Out 160 High BUN, Creat, low Na, low Hct, recent hosp, no ACE ⁄ BB
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; BB, b-blocker; BMI, body mass index; BP, blood pressure; BUN, serum urea
nitrogen; Creat, serum creatinine; Creat cl, creatinine clearance; DM, diabetes mellitus; EF, ejection fraction; HF, heart failure;
Hct, hematocrit; Hgb, hemoglobin; hosp, hospitalization; HR, heart rate; lymph, lymphocytes; Na, serum sodium; N ⁄ A, not available;
NYHA, New York Heart Association; RR, respiratory rate; 6 MW, 6-minute walk.
Table III. Clinical Risk Factors for
Mortality
Walk <1 block without dyspnea
Sodium <136 mEq ⁄ L
Serum urea nitrogen >40 mg ⁄ dL or
creatinine>1.8 mg ⁄ dL
Can’t tolerate ACEI ⁄ ARB ⁄ BB
Diuretic dose >1.5 mg ⁄ kg ⁄ d
Heart failure admission in the past
6 months
No clinical improvement with CRT therapy
or no CRT and QRS >140 ms
Hematocrit <35%
Abbreviations: ACEI, angiotensin-convert-
ing enzyme inhibitor; ARB, angiotensin
receptor blocker; BB, b-blocker; CRT,
cardiac resynchronization therapy.
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would they consider an LVAD. Just
over 40% stated that they would con-
sider such a therapy when they couldn’t
walk a block. Clearly, using exercise
tolerance as a marker of functional
status identifies a patient group that is
willing to undergo the therapies pro-
vided at an advanced HF center and
defines a group that would also benefit
from the therapy.
Laboratory Evaluation. Numerous stud-
ies have included either low sodium and
hematocrit values or high creatinine
and serum urea nitrogen values in their
prognostic values.19,23,25,26,28–36,38,39 The
majority of these studies used the abso-
lute value of these numbers in their
model, which makes it difficult to
choose a simple value. The numbers
chosen in this model, however, reflect
abnormal values that fall within a range
that has been shown to be predictive of
events.
Medication. The inability to tolerate
medications appears to be a very signifi-
cant marker for predicting poor out-
comes. Thirty-five percent of the
patients who died in the Teuteberg expe-
rience could not tolerate an ACE inhibi-
tor and only 38% were on a b-blocker.39
Similarly, the Seattle Heart Failure
Model (SHFM) demonstrates the effects
of intolerance of these medications.38
Conversely, the presence of a diuretic
and the absolute dose of a diuretic have
also been shown to be predictive of worse
outcomes.21,35,36,38 Based on data from
the SHFM, we decided on a furosemide
equivalent dose of 1.5 mg ⁄kg ⁄d as a mar-
ker of high-dose diuretic use.
HF Admissions. Admission to the hos-
pital for HF exacerbation has a 30% to
50% mortality rate during the next
year.35,37,39 Clearly this is a very impor-
tant marker of progression of disease and
reflects a group of patients with worse
outcomes.
CRT Therapy. Cardiac resynchroniza-
tion therapy (CRT) improves quality of
life and survival in patients with NYHA
functional class III and IV symptoms
and is now indicated as a therapy in
patients who have a QRS width
>0.12.5 Recently, Saxon and col-
leagues41 evaluated predictors of sudden
cardiac death and appropriate shock in
patients who had both an ICD and
CRT. They found that NYHA func-
tional class IV patients and worsening
renal function predicted appropriate
ICD therapy. In addition, appropriate
ICD therapy was associated with the risk
of death or all-cause hospitalization.
Patients who do not clinically respond
to this therapy and continue to be very
symptomatic should be thought of as
having a high risk for poor outcomes.
Call to Action
Despite significant improvements in
current HF therapies, HF continues to
be the number one discharge diagnosis
in the United States each year and is
associated with significant mortality. A
number of risk models have been
developed to predict patients with poor
outcomes, but they are rarely used
because of their complexity. A simple
prognostic model that includes vari-
ables routinely obtained at clinical vis-
its is required so that practitioners can
quickly identify and refer patients with
advanced HF symptoms before they
decompensate to the point that only
desperation therapies are available. Risk
factors such as those shown in
Table III should be used to determine
whether a patient with NYHA func-
tional class III or IV symptoms should
be referred for evaluation to an
advanced HF center. Using the flow
chart shown in Figure 2, those patients
can then be directed to the appropriate
therapy. In addition, a prospective vali-
dation study using simple risk factors
that can be easily obtained and used in
daily practice is necessary to further
advance the care of these patients.
Disclosures: Dr Russell is a consultant
and receives research support from
Thoratec Corporation. Dr Miller receives
research support from Thoratec
Corporation.
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